PHILADELPHIA – May 13, 2009 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that it will present key scientific data on its Attention Deficit Hyperactivity Disorder (ADHD) treatments lisdexamfetamine dimesylate (CII) and investigational non-scheduled guanfacine extended release, at a national scientific meeting of psychiatrists to be held May 16 -21 in San Francisco, CA.
"Shire is committed to the advancement of ADHD treatment research and eager to present results from a spectrum of studies," said Jeffrey Jonas, MD, Senior Vice President of Research & Development for the Specialty Pharmaceuticals business at Shire. "We believe the lisdexamfetamine dimesylate and guanfacine extended release study findings to be presented will contribute greatly to the growing body of research and development for physicians in the field of ADHD."
A summary of the key scientific presentations is provided below. Information about these data presentations mentioned in this release is embargoed until the respective presentation sessions have taken place at the meeting.
Lisdexamfetamine DimesylateMay 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTPharmacokinetics of Intranasal Versus Oral Administration of Lisdexamfetamine Dimesylate in Healthy AdultsPoster Presentation #NR2-027
May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTDuration of Effects of Lisdexamfetamine Dimesylate on Behavior of Children With Attention-Deficit/Hyperactivity Disorder in Naturalistic SettingsPoster Presentation # NR2-029
May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTPatient Experience and Satisfaction with Lisdexamfetamine Dimesylate in Adults With ADHDPoster Presentation #NR2-020
May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTResponse and Symptomatic Remission in a Long-Term Trial of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity DisorderPoster Presentation #NR2-054
May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTImprovement in Emotional Expression in Children with Attention-Deficit/Hyperactivity Disorder Treated with 20 to 70 mg/day Lisdexamfetamine DimesylatePoster Presentation #NR2-019
May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTImprovement in Executive Function in Children with Attention-Deficit/Hyperactivity Disorder Treated With 20 to 70 mg/Day Lisdexamfetamine DimesylatePoster Presentation #NR2-051
May 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTChanges in Emotional Expression Related to Medication Used to Treat Attention-Deficit/Hyperactivity DisorderPoster Presentation #NR2-038
Guanfacine Extended ReleaseMay 18, 2009; 12:30 PM to 2:00 PM PDT / 3:30 PM to 5 PM EDTEffects of Guanfacine Extended Release on Secondary Measures in Children With Attention-Deficit/Hyperactivity Disorder and Oppositional SymptomsPoster Presentation #NR2-060
Source: Porter Novelli